HPV Testing And Pap Test Industry Overview

The global HPV testing and Pap test market size was valued at USD 1.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 16.4% from 2021 to 2028.

Technological advancements, increasing number of cervical cancer screening programs, and high incidence of cervical cancer are some major factors driving the market for HPV testing and Pap test. However, the outbreak of Covid-19 and the implementation of restrictions to stay-at-home across the globe have rigorously reduced routine cancer screenings.

The decline in screenings was steep and swift; as of April 25, 2020, the decline recorded for breast and cervical cancer screening was 94%. During the lockdown, screening of cervical cancer decreased to 80% relative to the baseline, among the 1.5 million population of women is the Kaiser Permanente Southern California (KPSC) network. Segmenting the screening as per age, for women aged between 21 and 29, screening rates of cervical cytology per 100 individual months declined 78%. For women aged between 30 and 65, HPV test screening rates declined 82% per 100 person-months.

Gather more insights about the market drivers, restrains and growth of the Global HPV Testing And Pap Test Market

Cervical cancer is among the most common cancers among women above the age of 40. According to estimates from the WHO, cervical cancer is the fourth most frequent cancer, with approximately 570,000 cases and over 311,000 deaths in 2018. It is estimated that approximately 99% of cervical cancer cases are typically linked with HPV infections. Cervical cancer is mostly diagnosed among women aged between 35 and 44 with the average rate of diagnosis being at 50 years. According to data from the U.S. Department of Health and Human Services, the rate of new cervical cancer cases was estimated to be around 7.4 per 100,000 women, with the death rate being 2.2 per 100,000 women each year.

Growing demand for technologically advanced diagnostic procedures for screening cervical and vaginal cancers is one of the crucial factors expected to drive the market for HPV testing and Pap test over the forecast period. Various technological advancements, such as the development of HPV-type 16 E7-specific human immunologic assays used in non-HLA2 types, cobas system approvals, and usage of various molecular markers in screening procedures, are expected to drive the market for HPV testing and Pap test. In 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours. Similarly, researchers at Pathogen Discovery Laboratory have developed a diagnostic device that detects the presence of precancerous markers in HPV diagnosis.

Furthermore, the rising number of awareness programs by various organizations, such as the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening is one of the major factors expected to drive the market for HPV testing and Pap test during the forecast period. In March 2019, the U.K. government rolled out its first national cervical screening campaign called Cervical Screening Saves Lives. The campaign run by Public Health England (PHE) was initiated owing to a reduced number of screenings by women in the U.K. The campaign was used to facilitate increased awareness about the disease and initiate screening of the disease.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• Malaria Diagnostics Market: The global malaria diagnostics market size was valued at USD 728.8 million in 2021 and is anticipated to witness a CAGR of 5.4% during the forecast period. The rising demand for malaria diagnostics and the introduction of novel diagnostic techniques are the key factors driving the market.

• Neglected Tropical Diseases Diagnosis Market: The global neglected tropical diseases (NTD) diagnosis market size was valued at USD 6.09 billion in 2021 and is expected to expand at a CAGR of 4.4% during the forecast period. Growing awareness of NTDs and an increasing number of initiatives undertaken by the government are anticipated to fuel the market growth.

HPV Testing And Pap Test Market Segmentation

Grand View Research has segmented the global HPV testing and Pap test market on the basis of test type, application, product, technology, end-use, and region:

HPV Testing & Pap Test Type Outlook (Revenue, USD Million, 2016 - 2028)

• HPV Testing

• Pap Test

HPV Testing & Pap Test Application Outlook (Revenue, USD Million, 2016 - 2028)

• Cervical Cancer Screening

• Vaginal Cancer Screening

HPV Testing & Pap Test Product Outlook (Revenue, USD Million, 2016 - 2028)

• Instruments

• Consumables

• Services

HPV Testing & Pap Test Technology Outlook (Revenue, USD Million, 2016 - 2028)

• PCR

• Immunodiagnostics

• Other Technologies

HPV Testing & Pap Test End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals & Clinics

• Laboratories

• Others

HPV Testing & Pap Test Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America

• Europe

• Asia Pacific

• Latin America

• MEA

Key Companies profiled:

Some prominent players in the Global HPV Testing And Pap Test Market include

• Abbott Laboratories

• Qiagen N.V.

• Becton, Dickinson and Company

• Quest Diagnostics, Inc.

• Hologic, Inc.

• F. Hoffmann-La Roche

• Femasys, Inc.

• Arbor Vita Corporation

• NURX, Inc.

• Seegene, Inc.

• Thermo Fisher Scientific, Inc.

• bioMérieux SA

Order a free sample PDF of the HPV Testing And Pap Test Market Intelligence Study, published by Grand View Research.